• Earlier this month, Gilead Sciences reported that the FDA accepted its supplemental New Drug Application for Yeztugo (lenacapavir) 300‑mg tablets as a potential once‑weekly oral HIV PrEP option, with a Prescription Drug User Fee Act decision date set for February 2, 2027.
• The filing, backed by PURPOSE 1 and PURPOSE 2 trial data and aiming to introduce the first long‑acting oral PrEP, highlights how Gilead is seeking to broaden HIV prevention choices beyond its existing every‑six‑month injection.
• We’ll now examine how this bid for a first long‑acting weekly oral PrEP option could influence Gilead’s longer-term investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Gilead Sciences Investment Narrative Recap

To own Gilead today, you generally need to believe its HIV engine and growing oncology and liver portfolios can keep funding innovation, dividends, and buybacks, even as policy and pricing pressures bite. The new FDA review for once weekly oral Yeztugo adds to the HIV prevention story, but it does not change that near term sentiment is still tied to execution in HIV and oncology, and to how regulators and payers treat pricing.

The ISLEND 1 and ISLEND 2 results for the once weekly islatravir lenacapavir treatment regimen feel especially relevant here, because they point to a broader long acting HIV franchise built around lenacapavir. Together with the Yeztugo PrEP filing, they highlight both the opportunity to deepen Gilead’s HIV moat and the risk that heavy dependence on this area leaves earnings exposed to pricing shifts and competitive launches if these programs do not translate into durable uptake.

Yet against these promising HIV updates, investors should still be aware that...

Gilead Sciences' narrative projects $34.5 billion revenue and $10.8 billion earnings by 2029.

Uncover how Gilead Sciences' forecasts yield a $157.83 fair value, a 28% upside to its current price.

Exploring Other Perspectives

The most optimistic analysts were already assuming Gilead could lift revenue to about US$38.1 billion and earnings to US$12.7 billion by 2029, so compared with the baseline focus on pricing and patent risks, this Yeztugo news could eventually tilt that bullish narrative even further if long acting HIV really takes off.

Explore 7 other fair value estimates on Gilead Sciences - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Gilead Sciences research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Gilead Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Gilead Sciences' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.